OVARIAN CANCER

This study tests a new targeted therapy, sacituzumab tirumotecan (Sac-TMT), as maintenance treatment for people with advanced ovarian cancer that is not HRD positive. After initial chemotherapy, participants will receive Sac-TMT with or without bevacizumab, or standard care. The …

This early-phase study tests a new treatment called CIML NK cell therapy for people with recurrent ovarian cancer that no longer responds to platinum-based chemotherapy. The therapy uses specially trained natural killer cells from a donor to attack the cancer. The study aims to f…

This study tests two drugs, fuzuloparib and apatinib, given before surgery to people with advanced ovarian cancer that has a specific gene change called HRD. The goal is to shrink tumors enough for complete removal and avoid chemotherapy. About 48 participants will take these pil…

This study tests a new drug, KESONOTIDE™, in people with advanced solid tumors like prostate, breast, lung, ovarian, pancreatic, skin cancer, or glioblastoma. The main goal is to check if the drug is safe and tolerable, and to find the right dose. About 80 adults will take part i…

This program provides an experimental drug called AVM0703 to people with various cancers, including brain tumors, breast cancer, and leukemia. It is available in the US when a doctor requests it. So far, 37 patients have received the treatment, and side effects have been mostly m…

This study tests whether adding a vitamin A-like drug (ATRA) to a platelet-boosting medication (romiplostim N01) works better than the platelet drug alone for cancer survivors whose platelet counts stay low after chemotherapy. About 220 adults with gynecologic, breast, or lung ca…

This study tests a new drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, ovarian, lung, head and neck, esophageal, or cervical cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and shrinks tu…

This study tests whether a combination of three drugs—pembrolizumab, bevacizumab, and low-dose cyclophosphamide—can help control high-grade ovarian cancer that still has small amounts of disease after initial therapy. About 20 women aged 18 and older with this type of ovarian can…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive solid tumors that have spread and are not responding to other treatments. About 100 people will be followed to see if their tumors shrink and how long that lasts. The goal is to provide a trea…

This early-stage study tests a new treatment called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, and ovarian cancers. The therapy uses a patient's own immune cells, modified to recognize and attack cancer cells that have a specific marke…

This early-phase study tests an experimental pill called ATX-295 in people with advanced solid tumors, including ovarian and breast cancers that have not responded to standard treatments. The drug works by blocking a protein (KIF18A) that cancer cells need to divide. The main goa…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety and find the best dose. About 470 adults will take part to see if the drug can he…

This study tests whether adding bevacizumab to niraparib after standard chemotherapy works better than niraparib alone for women with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. About 970 participants will be randomly assigned to one of two treatment p…

This study tests whether using a special camera and fluorescent dye during surgery can help surgeons see blood flow in the bowel and reduce the risk of leaks after the operation. About 310 women with ovarian cancer who need bowel surgery will take part. The goal is to see if this…

This early-stage study tests a new drug called PHST001, alone or with chemotherapy, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the best dose. The study includes people with ovarian, endomet…

This study tests different immunotherapy drug combinations in women with a type of ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see which combinations can shrink tumors or slow the cancer's growth. About 60 participants will join this phase 2 tr…

This early-phase study tests a new drug, CLSP-1025, in adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have a specific genetic change called p53 R175H and a certain immune type (HLA-A*02:01). The goal is to find a safe dose and see if the drug can …

This early-phase study tests a new drug called SLV-154 in about 70 people whose solid tumors (like head and neck, lung, breast, or ovarian cancer) have spread. The main goal is to find a safe dose and watch for side effects. Participants must have a confirmed diagnosis and be in …

This trial tests a personalized cancer vaccine made from tumor cells grown in a lab. The cells are modified to boost the immune system, then killed and injected into the patient. The goal is to help people with metastatic melanoma, breast, ovarian, colorectal, gastric, lung, or k…

This study is for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific genetic feature (HRD). The trial tests whether taking a combination of two drugs (a PARP inhibitor and an angiogenesis inhibitor) after initial treatment can help keep…

This study tests a new drug called ACE-86225106 in adults with advanced solid tumors (like ovarian, breast, or prostate cancer) that are hard to treat or no longer respond to standard therapy. The goal is to see if the drug is safe, tolerable, and can shrink tumors. About 298 par…

This early-phase study tests a personalized cell therapy (B7-H3 CAR T cells) in 48 adults with ovarian cancer that has returned and no longer responds to standard chemotherapy. The treatment involves taking a patient's own immune cells, reprogramming them to better recognize and …

This study tests a new drug (LBL-024) combined with a standard chemotherapy (paclitaxel) in people with ovarian cancer that no longer responds to platinum-based treatments. About 110 adults will receive the combination to see if it shrinks tumors and how safe it is. The goal is t…

This study tests an experimental drug called COM701 in people with ovarian cancer that came back after treatment but still responds to platinum chemotherapy. The goal is to see if COM701, given as a maintenance therapy every three weeks, can delay cancer progression longer than a…

This study tests a new treatment for people with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, remove white blood cells, modify them in the lab to recognize and attack CD70, and then give t…

This study tests a new way to manage blood pressure and fluids during complex ovarian cancer surgery. The approach uses artificial intelligence to help doctors keep blood pressure stable and avoid giving too much fluid. The goal is to reduce serious complications like kidney inju…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, such as certain ovarian, endometrial, and lung cancers. The drug is designed to target and attack cancer cells that have a specific marker (PTK7). The main goals are to find the safest do…

This study tests a new treatment for advanced ovarian cancer using a patient's own immune cells that are modified in the lab to better attack the cancer. About 100 adults with stage III or IV ovarian cancer that has come back after initial treatment will receive these modified ce…

This early-phase study tests an experimental drug called IVX037, injected directly into tumors, for people with advanced colorectal, gastric, or ovarian cancers that have stopped responding to standard treatments. The study has two parts: first, testing IVX037 alone, and then com…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better reduce cancer before surgery in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly as…

This study tests a new drug called SHR-A1811 combined with standard chemotherapy (carboplatin and bevacizumab) in 150 women whose ovarian cancer has returned after initial platinum-based treatment. The goal is to find the safest dose and see if the combination shrinks tumors or s…

This study tests a new drug called TUB-040 in people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate designed to deliver a cancer-killing agent directly to tumor cells th…

This phase 3 trial tests whether a new drug called SHR-A1811 works better than standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 300 participants will be randomly assigned to…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study tests an experimental drug, REGN5668, alone or with other immune-boosting medicines in people with ovarian, fallopian tube, peritoneal, or endometrial cancers. The goal is to find the safest dose and see if the combination shrinks tumors. About 612 adults whose cancer …

This early-phase study tests an experimental oral drug, RGT-490, in adults with advanced solid tumors (including breast, ovarian, and endometrial cancers) that have a specific genetic change called PIK3CA. The main goals are to check the drug's safety, find the right dose, and se…

This early-stage study tests a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to prior treatments. The main goals are to check if the drug is safe and to find the best dose. About 282 participants will receive the…

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Niraparib blocks cancer cells from repairing their DNA, which may slow or stop tumor growth. Researchers will track side effects and ex…

This early-stage study is testing a new drug called SYN818 combined with olaparib in adults with advanced solid tumors (like ovarian or breast cancer) that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 110 part…

This early-phase study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer) that have not responded to other treatments. The main goals are to check safety, find the right…

This study tests an experimental pill called INX-315 in 150 people with advanced cancers, including certain breast and ovarian cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study has three…

This study tests whether adding a targeted drug (olaparib) to heated chemotherapy during surgery can safely treat advanced ovarian cancer. About 55 adults with stage III ovarian cancer will receive the drug before and during surgery. The goal is to find the best dose and check fo…

This study tests whether giving the drug niraparib again after surgery can help women with ovarian cancer whose disease has come back in just a few spots. About 30 participants will take niraparib pills for as long as they work. The goal is to see if this approach can delay the c…

This study looks at whether removing enlarged lymph nodes in the chest (cardiophrenic area) during surgery can help people with advanced ovarian cancer live longer without the cancer coming back. About 52 women with stage III or IV ovarian cancer will take part. The goal is to se…

This study tests a new drug, INCB123667, against standard chemotherapy in people with a type of ovarian cancer that no longer responds to platinum-based treatments. The trial includes about 466 adults whose tumors have a specific marker called cyclin E1 overexpression. The goal i…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors (like colorectal, lung, or pancreatic cancer) that have lost a specific marker on their cells. The treatment uses the patient's own immune cells, modified to target cancer cells while protecti…

This study tests a new drug called HS-20089 against standard chemotherapy in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 468 women aged 18 and older will be randomly assigned to receive either H…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in people with ovarian cancer that has come back after treatment with PARP inhibitors. The drug targets a protein called HER2 found on some cancer cells. About 116 adults with HER2-positive ovarian cancer will be rando…

This early-phase study tests an investigational drug called BL0175 in postmenopausal women with advanced breast, ovarian, or endometrial cancer that is hormone receptor-positive. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink or cont…

This study tests a special program called PROADAPT for women aged 70 and older (or 60+ with health issues) who have advanced ovarian cancer and need surgery. The program includes nutrition advice, physical exercises, and education before surgery, plus extra support during the hos…

This study tests whether the drug belzutifan can shrink or control certain gynecologic cancers (like ovarian, endometrial, cervical, vaginal, or vulvar) that have come back or not gone away. About 32 adults with clear cell carcinoma will receive belzutifan pills. The main goal is…

This study tests an experimental drug called ART0380 in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with other chemotherapy drugs like gemcitabine or irinotecan. About 442 participants wi…

This early-stage study tests a new experimental drug (NMS-03305293) combined with a standard chemotherapy (topotecan) in 24 people whose ovarian cancer has returned after prior treatments. The main goals are to check safety and find the best dose, while also seeing if the combina…

This study tests whether two drugs, hydroxychloroquine and nelfinavir, can help keep high-grade serous ovarian cancer from coming back when added to standard maintenance therapy. About 38 women with platinum-sensitive recurrent ovarian cancer will take these drugs alongside bevac…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 adults who have already had two rounds of chemotherapy will…

This study tests an experimental drug called ubamatamab, alone or with other cancer drugs, in people with advanced ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see how safe and effective these combinations are. About 220 participants w…

This study tests a new drug called XNW28012 in adults with advanced solid tumors (like pancreatic, ovarian, cervical, or colorectal cancer) that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 350 people…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This study tests whether adding trastuzumab deruxtecan (T-DXd) to standard bevacizumab maintenance therapy helps women with advanced HER2-expressing ovarian cancer live longer without their cancer growing. About 582 participants will receive either the combination or bevacizumab …

This early-phase study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatm…

This early-stage trial tests a custom-made immunotherapy called Innocell for women whose ovarian cancer has returned after standard treatment. The therapy uses the patient's own tumor tissue to create a personalized vaccine-like treatment. The main goals are to check safety and s…

This study is for women with advanced ovarian cancer that has been fully removed by surgery. It compares 3 cycles of chemotherapy followed by the maintenance drug niraparib against the standard 6 cycles plus niraparib. The goal is to see if the shorter chemo course works just as …

This study tests a new treatment using specially engineered natural killer (NK) cells that target a protein called TROP2 found on cancer cells. The cells are given directly into the abdomen to people with ovarian or pancreatic cancer that has stopped responding to standard treatm…

This study tests a new treatment called EBNK-001, which uses donor natural killer (NK) cells to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive the NK cells along with ch…

This study tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer. About 44 participants will receive different doses to find the safest and most effective one. The goal is to control the disease and reduce tumors, n…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, lung, or ovarian cancer) that have not responded to standard treatments. The goal is to find a safe dose and see if the drug shrinks tumors, either alone or combined with ot…

This study looks at whether having surgery after chemotherapy helps people with recurrent ovarian cancer live longer without the disease getting worse. About 80 participants who have already responded to chemo will be randomly assigned to either have surgery or not. The goal is t…

This early-phase trial tests whether adding lurbinectedin to standard chemotherapy (paclitaxel and bevacizumab) can better control platinum-resistant ovarian cancer. About 34 adults with advanced ovarian, fallopian tube, or peritoneal cancer will take part. The main goal is to ch…

This study is for people with advanced ovarian, fallopian tube, or peritoneal cancer that has a specific marker called folate receptor alpha. Participants will receive a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab) before and after surgery. The goa…

This early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…

This study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either stand…

This study tests a new drug called datopotamab deruxtecan (Dato-DXd) alone or with other cancer drugs in people with advanced solid tumors that have spread. The goal is to see if the drug can shrink tumors or slow cancer growth. About 454 adults with cancers like endometrial, gas…

This study tests whether a weekly chemotherapy schedule works better than the standard every-3-week schedule for people with a hard-to-treat type of ovarian cancer. Participants have already had some chemo but their tumors are not shrinking well and cannot be fully removed by sur…

This early-phase trial tests a one-time treatment called OPB-101 for people with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to ch…

This study tests a new drug called AZD8205, alone or with other cancer drugs, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have spread or come back. The main goals are to check safety and find the right dose. About 460 adults whose cancer has n…

This study tests a treatment using donor immune cells (CAR-NK cells) designed to attack cancer. The specific target on the cancer cells is chosen based on a biopsy of the tumor or a blood test. The goal is to see if this approach is safe and can shrink or control advanced solid t…

This early-stage study tests a new drug called TORL-1-23 in people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 90 participants will take part.

This early-stage trial tests a new drug called BI-1808, alone or with another drug (pembrolizumab), in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not responded to standard treatments. The main goals are to check safety, find the bes…

This study tests a new method called PIPAC, which delivers chemotherapy as a spray directly into the abdomen, for people with advanced ovarian cancer. The goal is to see if it works better than standard chemotherapy given through a vein. About 60 adults aged 18-70 with high tumor…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. About 27 adults will take part in this …

This early-stage study tests a new treatment for ovarian cancer that has come back after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to find a safe dose and understand…

This study tests a technique called acute normovolemic hemodilution (ANH) during ovarian cancer surgery. Before surgery, some blood is removed and replaced with fluids, then returned later. The goal is to see if this reduces the need for donor blood transfusions. About 86 adults …

This study tests whether adding heated chemotherapy directly into the abdomen during surgery can help people with advanced ovarian cancer live longer. It includes 520 adults with stage 3 or 4 ovarian cancer who have already received some chemotherapy. Participants are randomly as…

This study tests whether a new version of the drug olaparib (DWZ2501) works the same as the current version (DWC202510) in women with advanced BRCA-mutated ovarian cancer. About 40 participants will take both versions at different times to compare drug levels and side effects. Th…

This early-stage study tests a new oral drug, NKT5097, in 205 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find the safest dose and understand side effects. The study focuses on breast cancer and other tumors with specific g…

This study tests an experimental drug called INCB123667 in people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. About 160 participants will receive the drug to see if it can shrink tumors or slow …

This study is testing a new robotic surgery system (Medtronic Hugo™) to see if it is safe and works well for hysterectomy. About 70 adult women with conditions like fibroids, endometriosis, or certain cancers will take part. The main goal is to see if the surgery can be completed…

This early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. About 319 participants will receive the drug to…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study tests a new drug called CUSP06 for people with ovarian cancer or other solid tumors that have stopped responding to standard treatments. The drug works like a guided missile, targeting a protein on cancer cells to deliver a powerful toxin directly. The main goals are t…

This study tests a drug called valemetostat in people with advanced solid tumors that have certain gene changes (like SMARCB1 or ARID1A). The drug aims to reactivate protective genes to slow or stop cancer growth. About 900 adults will take the drug daily for up to 2 years, with …

This early-phase study tests a new drug (DT2216) combined with standard chemotherapy (paclitaxel) in 30 people with ovarian cancer that has returned and is resistant to platinum-based treatments. The main goal is to find the safest dose of DT2216 when given with paclitaxel, and t…

This study tests whether a daily pill called isoquercetin (a natural compound found in fruits) can reduce blood markers linked to dangerous clots in people with ovarian cancer. About 90 participants receiving first-line chemotherapy will take either isoquercetin or a placebo for …

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically engineer them in a lab to recognize and attack unique mutations in their tumor, and then infu…

This study tests a three-drug chemotherapy and immunotherapy combination given before surgery, followed by maintenance therapy after surgery, in 20 people with newly diagnosed stage III or IV ovarian cancer. The goal is to see if this approach delays cancer progression. Participa…

This phase 3 trial tests whether adding the experimental drug IMNN-001 to standard chemotherapy improves survival in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 500 newly diagnosed participants will receive either the combination or chemother…

This study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people whose ovarian or endometrial cancer has returned but still responds to platinum-based treatments. The goal is to find the safest and most effective dose and see how well it shrinks tumors.…

This study tests a new drug (distamab vedotin) combined with carboplatin for people with advanced ovarian cancer that has a specific protein called HER2. The goal is to see if this combination works better and has fewer side effects than standard chemotherapy. About 20 participan…

This early-phase study tests a new drug called NRM-823, alone or with an immunotherapy, in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. The study includes several cancer types lik…

This early-phase study tests a new treatment called 177LuBetaBart for people with advanced solid tumors that have stopped responding to standard therapies. The treatment combines a targeting antibody with a radioactive particle to deliver radiation directly to cancer cells. The s…

This study tests a new drug called ETX-19477 in people with advanced solid tumors (like breast, ovarian, or prostate cancer) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors or slow their growth. About …

This early-phase study tests an investigational drug called ABBV-901, given alone or with a standard drug (bevacizumab), in about 207 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if tumors shrink.…

This early-phase study tests an experimental drug called BL-M07D1 in 280 adults with advanced solid tumors that have the HER2 protein. The goal is to see if the drug is safe and can shrink tumors in cancers like breast, lung, stomach, and ovarian cancer. Participants must have tr…

This early-stage study is testing a new drug, AOH1996, in adults with solid tumors (like lung, ovarian, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and understand side effects. The drug works by blocking certai…

This study tests a drug called relacorilant combined with other treatments for people with ovarian, fallopian tube, peritoneal, or endometrial cancers. About 270 participants will join to see if the combination helps slow cancer growth. The goal is to control the disease, not cur…

This study tests if surgery followed by heated chemotherapy directly in the abdomen can help women whose mucinous ovarian cancer has come back. About 30 participants will receive this combined treatment. The goal is to see how long they live without the cancer growing again.

This early-phase study tests a new drug called LNCB74 in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. LNCB74 is an antibody-drug conjugate designed to deliver a cancer-killing agent dir…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 participants wi…

This early-phase trial tests an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The main goals are to find a safe dose, understand side effects, and see if the drug can slow tumor…

This study tests a new drug called HLX43 in people with advanced cervical or ovarian cancer that came back or spread after standard first treatment. The drug targets a protein on cancer cells to deliver a toxin directly. About 190 adults will receive the drug to see if it shrinks…

This study tests whether adding the experimental drug Rina-S to standard therapy helps keep ovarian cancer from coming back. About 528 people with platinum-sensitive ovarian cancer will receive either Rina-S alone, Rina-S plus bevacizumab, bevacizumab alone, or monitoring only. T…

This study tests an experimental drug called mirvetuximab soravtansine (MIRV) combined with either bevacizumab or carboplatin in people with a specific type of ovarian cancer. About 320 participants will receive different doses to find the safest and most effective treatment. The…

This study tests a new drug called APL-5125 in about 100 adults with advanced solid tumors, including colorectal, pancreatic, and ovarian cancers. The goal is to check safety and see if the drug can shrink tumors. Participants must have tried standard treatments first.

This early-stage study tests a new cancer treatment called FT836, a ready-made immune cell therapy, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers. The treatment is given alone or with chemotherapy and/or antibod…

This early-phase study tests a new drug called EXS74539 in about 40 adults with advanced solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for signs that the drug shrin…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific genetic mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 uses a patient's own immune cells, which are …

This study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance treatments: one with niraparib alone and another with niraparib plus bevacizumab. The goal is to see which combination better delays cancer from return…

This early study tests a new treatment called SY001 for people with advanced ovarian or pancreatic cancer that has not responded to at least one prior therapy. SY001 uses specially engineered immune cells (CAR-macrophages) to target a protein called mesothelin found on cancer cel…

This study is for people under 30 with disorders of sex development who are at high risk of infertility or ovarian cancer. Researchers will remove and freeze ovarian tissue before it is surgically removed for medical reasons. The goal is to see if this tissue can later be used to…

This study tests an experimental drug called AZD5335, alone or with other cancer treatments, in people with advanced ovarian, lung, or endometrial cancers that have not responded to standard therapy. The main goals are to check safety and find the right dose. About 506 participan…

This early-stage trial tests whether a new type of immune cell therapy is safe for people with ovarian cancer that has come back. The treatment uses a patient's own T cells, which are modified in a lab to recognize and attack cancer cells that have a specific marker (FSHR). Up to…

This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with a hard-to-treat type of ovarian cancer (platinum-resistant). About 33 adults with high-grade serous ovarian cancer that has stopped responding to platinum-based chemo…

This early-stage study tests a one-time treatment called SynKIR-110, made from a patient's own immune cells modified to attack cancer cells that have a protein called mesothelin. It is for adults with advanced ovarian cancer, bile duct cancer, or mesothelioma that has come back a…

This study tests whether adding mirvetuximab soravtansine to standard maintenance therapy (bevacizumab) can delay cancer regrowth in people with a specific type of ovarian, fallopian tube, or peritoneal cancer. Participants must have cancer that responded to initial platinum-base…

This early-stage study tests a new drug, QXL138AM, for safety in about 100 people with advanced solid tumors (like ovarian, pancreatic, lung, or breast cancer) or multiple myeloma. Participants must have tried other treatments without success. The study will find the right dose a…

This study tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein. Participants must have already tried at least one other cancer treatment. The goal is to see if the drug can shrink tumors or stop them from growing. This is not…

This early-stage trial tests a new treatment called THEO-260, a virus designed to attack cancer cells, in people with advanced ovarian cancer that no longer responds to platinum chemotherapy. The study will give different doses directly into the abdomen to find the safest dose an…

This study tests a new treatment that delivers a powerful, short-range radioactive particle directly to cancer cells that have a protein called FAP on their surface. The therapy is given in two steps: first a low-dose imaging version to see if the tumor takes up the drug, then a …

This study is testing whether a combination of three drugs can help control recurrent ovarian cancer. It will involve about 20 adults whose cancer has returned after initial treatment. The main goals are to see if the treatment shrinks tumors and to understand what side effects p…

This study aims to see if ultrasound images of healthy ovaries can predict whether a woman carries a harmful BRCA gene mutation, which raises the risk of breast and ovarian cancer. Researchers will develop a computer model using thousands of images from over 6,400 women. If succe…

This study explores whether a tampon can collect samples to detect endometrial (uterine) and ovarian cancer early. Researchers will analyze DNA and proteins from tampons used by 1,500 women before surgery. The goal is to develop a simple, non-invasive screening tool that could ca…

This study aims to see if combining the standard CA125 blood test with other tumor markers can help detect ovarian cancer earlier in women who are at low risk. About 8,000 postmenopausal women aged 50-75 who have at least one ovary and are cancer-free will give blood samples over…

This study tests a drug called Gleolan that makes ovarian cancer cells glow during surgery, helping surgeons see and remove tumors they might otherwise miss. About 170 adults with suspected or confirmed ovarian cancer will take part. The goal is to see if Gleolan improves tumor r…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This study is testing whether yearly vaginal ultrasound can accurately detect ovarian cancer in women at intermediate to high risk, while reducing unnecessary false alarms. Researchers will screen 65,000 women from Kentucky over time and track how often the test correctly identif…

This study is testing a new type of PET scan that uses a special tracer to find a protein called Trop2 on cancer cells. The goal is to see if this scan can detect and monitor many types of solid tumors more accurately than current methods. About 400 adults with or suspected of ha…

This study is testing a new blood test that looks for tiny particles (called extracellular vesicles) which may help detect ovarian cancer earlier. Researchers will collect blood samples from 1,500 postmenopausal women aged 50–74 in Queensland, Australia. The goal is to see if the…

This study is testing a new imaging agent called 18F-T2, which targets a protein (CAIX) found on many solid tumors. About 200 adults with cancers like kidney, bladder, colorectal, or lung cancer will receive a PET/CT scan using this agent. The goal is to see if it can find tumors…

This study aims to create a test that can find endometrial, ovarian, and cervical cancers by looking for specific DNA markers in vaginal fluid or blood. Researchers at Mayo Clinic will collect samples from over 3,000 women to see how well the test works. The goal is to make cance…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including breast, lung, and colon cancer. Researchers want to see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before symptoms appear. About …

This study is testing a new blood test that uses laser technology and artificial intelligence to find early signs of breast, colon, pancreatic, ovarian, and lung cancers. Researchers will collect blood samples from 1,400 people aged 45 and older who have or are suspected to have …

This study is testing whether changes in platelet RNA can help doctors diagnose ovarian cancer earlier and more accurately. Researchers will collect blood samples from 245 women—those with an ovarian mass and healthy volunteers—to see if this new approach works. If successful, it…

This study looks at whether the things people buy at stores—like painkillers or indigestion remedies—could be early warning signs of cancer. Many cancers cause vague symptoms that people treat with over-the-counter products before seeing a doctor. Researchers will compare the sho…

This study is testing a new platform that uses advanced testing to better understand different types of cancer, including leukemia, myeloma, and solid tumors. The goal is to see if this platform can change the recommended treatment for patients, making it more personalized. About…

This study tests whether drinking tart cherry juice can help prevent nerve damage (neuropathy) caused by the chemotherapy drug paclitaxel in people with breast or ovarian cancer. About 86 participants will be randomly assigned to take either a high or low dose of the juice daily …

This study looks at whether removing the fallopian tubes first and delaying ovary removal is as safe as removing both at once for preventing ovarian cancer in women with BRCA or other high-risk gene mutations. About 100 premenopausal women aged 25-50 will choose their preferred s…

This study looks at whether removing the fallopian tubes first and delaying ovary removal is a safe way to prevent ovarian cancer in women with BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1 gene mutations. About 3,000 women will take part. The goal is to see if this two-step approach wo…

This study looks at whether different types of preventive surgery can lower the chance of getting ovarian cancer in women with certain gene changes (like BRCA). About 480 women will choose between standard surgery, delayed ovary removal, or close monitoring. Researchers will trac…

This early-phase study tests whether a single dose of psilocybin, given with therapy, can reduce the intense fear of cancer returning in women who have completed treatment for early-stage breast or ovarian cancer and are now in remission. Twenty participants will receive preparat…

This early-phase study tests whether fecal microbiota transplantation (FMT) can safely reduce severe diarrhea or colon inflammation caused by immune-checkpoint inhibitors in people with genitourinary and other cancers. About 40 participants will receive FMT and be monitored for s…

This study tests whether the drug riluzole can prevent memory and thinking problems (often called 'chemo brain') in people receiving chemotherapy for various cancers. About 24 adults with breast, lung, or other cancers will receive either riluzole or a placebo during their chemo.…

This study looks at whether a program of exercise and nutrition during chemotherapy can help elderly patients (65+) with ovarian or pancreatic cancer get stronger before surgery. About 22 participants will follow the program to see if they can stick with it. The goal is to improv…

This study tests whether a 16-week home-based exercise program (aerobic and strength training) is practical and helpful for women with advanced ovarian or endometrial cancer who are starting chemotherapy after surgery. Researchers want to see if it improves leg function and reduc…

This study offers a yoga-based program to women with advanced ovarian cancer who are getting chemotherapy before surgery. The goal is to see if the program is practical and helps improve quality of life. About 40 participants will take part in virtual yoga sessions designed to su…

This study tests a supportive telehealth program called REVITALIZE to see if it can reduce how much fatigue interferes with daily life for adults with advanced ovarian cancer who are taking PARP inhibitor maintenance therapy. About 240 participants will either receive the REVITAL…

This study tests a short counseling program called CALM for women with advanced ovarian cancer. The goal is to see if it's practical and helpful for reducing stress and improving well-being. Participants will fill out questionnaires and may receive up to 6 therapy sessions.

This study tests a tool called CASI that helps ovarian cancer patients, their caregivers, and doctors set a shared plan for each doctor visit. The goal is to make conversations more focused and helpful. About 112 people with advanced ovarian cancer and their caregivers will take …

This study looks at whether a program of exercise, nutrition advice, and mental support before surgery (called prehabilitation) can help people with ovarian or endometrial cancer recover faster and feel better. About 64 patients will be randomly assigned to either standard care o…

This early-phase study is testing whether adding aspirin to standard chemotherapy can reduce immune-suppressing cells inside ovarian, fallopian tube, or peritoneal tumors. About 100 women will take aspirin alongside their chemo before surgery. The goal is to see if this simple, l…

This study is testing whether a virtual mind-body program called Integrative Medicine at Home (IM@Home) can help people with head and neck, thoracic, gynecologic, or other cancers feel less tired and have a better quality of life while receiving treatments like chemotherapy or ra…

This study looks at how the antifungal drug itraconazole changes the levels of a cancer drug in the blood of people with ovarian, primary peritoneal, or fallopian tube cancer. About 24 participants will take both drugs in a fixed order to measure drug levels over time. The goal i…

This study looks at whether a digital app can help cancer patients get genetic testing directly from their oncologist, instead of visiting a separate genetics clinic. The goal is to see if this approach reduces patient distress and improves care. About 180 adults with breast, pro…

This study looks at the bacteria and natural chemicals in the vagina to see if they can help find ovarian cancer earlier. Researchers will collect samples from 50 healthy women (who still have ovaries) and compare them to samples from women with a higher cancer risk or known ovar…

This study follows 1,000 women newly diagnosed with ovarian, fallopian tube, or primary peritoneal cancer to see how their genes (BRCA and HRD) affect their response to standard chemotherapy and surgery. Researchers will track treatment outcomes, including how much cancer is remo…

This study aims to identify women at risk for hereditary breast, ovarian, and colorectal cancers by offering genetic screening and counseling at mobile mammography units. About 1,000 underserved women in Texas will be invited to participate when they come for their routine mammog…

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecological cancers (cervical, endometrial, ovarian, or vulvar). Researchers will follow 120 women receiving immunotherapy plus chemotherapy and…

This study looks at 88 women with advanced ovarian cancer to compare two tests that check for a DNA repair problem called HRD. The tests help doctors see if the cancer is likely to respond to platinum chemotherapy and if a PARP inhibitor drug might help. The goal is to learn whic…

This study aims to create and improve educational materials about genetic testing for people with breast, ovarian, prostate, pancreatic, or colorectal cancer. Researchers will interview 445 participants from diverse cultural and language backgrounds to get their feedback. The goa…

This study looks at how ovarian cancer is currently treated in Brazil. Researchers will collect information from 250 patients to see what is working well and what could be improved. The goal is to use these findings to set better quality standards for ovarian cancer care across t…

This study is for people with advanced ovarian cancer whose disease has stopped responding to platinum-based chemotherapy. Researchers will collect archived tumor tissue to test a method called DRP, which aims to predict whether certain investigational cancer drugs might be effec…

This study aims to understand how ovarian cancer affects the immune system, especially in the bone marrow and blood. Researchers will compare immune cells from 90 women with ovarian cancer to those without cancer. The goal is to find new ways to boost the immune system to fight t…

This study is collecting blood and tumor samples from 1100 people with various cancers (like head and neck, ovarian, and lung cancer) to learn how immune cells called T cells behave. The goal is to understand why some cancers are better at hiding from the immune system. Participa…

This study looks at how chemotherapy for ovarian cancer may change thinking and memory. Researchers will test 18 patients before, during, and after treatment using simple mental exercises. The goal is to better understand these side effects, not to test a new treatment.

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study aims to collect information from cancer patients (breast, lung, ovarian, multiple myeloma, or AML) using weekly online surveys about their symptoms. The goal is to build a database that helps doctors better understand and manage side effects during treatment. Participa…

This study aims to collect and analyze genetic data from 300 Taiwanese women with ovarian cancer to better understand the disease and find new treatment targets. Participants provide tumor tissue and medical history but do not receive any experimental treatment. The goal is to bu…

This observational study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for possible futur…

This study looks at whether watching a video before genetic testing helps people with certain cancers understand their hereditary risk better. About 1020 adults with breast, ovarian, pancreatic, prostate, colorectal, renal, melanoma, or sarcoma cancers will take part. Researchers…

This study looks at whether a polygenic risk score (PRS) can help predict the chance of developing ovarian cancer. Researchers will compare the PRS of 1300 Italian women with and without ovarian cancer. Participants will fill out a questionnaire and give a blood sample for geneti…

This study is building a platform to better understand a person's risk of developing cancer or having it come back. Researchers will analyze blood samples from 850 people with certain cancers to find genetic markers, immune system changes, and other biological clues. The goal is …

This study takes tumor samples from people with breast, colorectal, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to match patients with effective treatments and…

This study looks at how chemotherapy given before surgery affects frailty in adults over 55 with advanced ovarian or endometrial cancer. Researchers will track changes in an electronic frailty score and check for thinking problems. The goal is to see if chemo helps patients becom…

This study is a large registry that will follow about 2,000 people in Germany with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how their disease progresses, and their quality of life. The goal is to bet…

This study is developing an AI-powered blood test to find cancer early and see how well treatments are working. Researchers will analyze blood samples from 6,000 adults with or without cancer to identify unique RNA signals in platelets and immune cells. The goal is a safe, non-in…

This study collects blood or cheek swab samples from people with cancer who are already in treatment at the National Cancer Institute. Researchers will analyze the DNA to find genetic differences that may affect how the body processes cancer drugs and whether side effects occur. …

This study looks at 50 women with ovarian cancer that came back quickly after treatment. The goal is to collect information about their health and tumors to help doctors better predict outcomes and plan care. No new treatment is being tested; instead, researchers are observing an…

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The goal is to see how the body absorbs and handles the radiation from RAD301, and whether it…

This study collects blood and leftover tissue samples from 9,600 adults with different types of cancer, such as breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for tiny bits of cancer DNA in the blood, which may help detect if ca…

This study aims to find biological markers in tumor, blood, and other samples from 350 ovarian cancer patients. Researchers will track how these markers change with treatment and relate to outcomes like progression-free survival. The goal is to better understand why some cancers …

This study looks at whether keeping the left colic artery intact during surgery for colorectal or ovarian cancer helps maintain better blood flow to the colon. About 50 adults scheduled for left-sided colon, rectal, or ovarian cancer surgery will participate. Researchers will mea…

This study aims to collect and analyze genetic information from 25,000 adults who either have cancer or are at risk of developing it. Researchers will look at tumor DNA and other health records to better understand what drives different cancers. The goal is to find new ways to de…

This study looks at whether a family history screening program can help more women in rural public health clinics learn about their risk for BRCA-related breast and ovarian cancers. About 3,200 women over age 25 in Southwest Georgia will take part. The goal is to see if the progr…

This study aims to collect blood samples (liquid biopsies) from 2,500 people with cancer or at high risk for cancer, along with their medical information. The samples will be stored and used by researchers to develop better ways to detect, monitor, and understand cancer over time…

This study is looking for genetic targets in ovarian cancer, especially a common type called high-grade serous ovarian carcinoma. Researchers will study tissue samples from 180 women to find genes that might help diagnose or treat the disease. The goal is to better understand the…

This study aims to create and test a simple, Spanish-language tool that helps patients with ovarian cancer make informed decisions about their ongoing (maintenance) therapy. Researchers will work with 70 Spanish-speaking patients and their doctors to see if the tool reduces regre…

This study aims to see if lab-grown tumor models can predict how well heated chemotherapy (HIPEC) works during surgery for cancers that have spread to the abdomen. About 60 adults whose tumors cannot be fully removed safely will take part. Researchers will compare tumor responses…

This study observes 750 women with advanced ovarian cancer in Germany who are starting first-line platinum-based chemotherapy. It collects information on how patients are treated, their experiences, and outcomes like cancer progression. The goal is to learn more about the effecti…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find ovarian cancer recurrence earlier than current methods like CT scans or CA-125 blood tests. About 30 women with advanced ovarian cancer will give blood samples over time during their follow-up. I…

This study looks at how well patients aged 70 and older with advanced ovarian cancer tolerate PARP inhibitors, a type of targeted cancer drug. Researchers will track side effects and dose adjustments in 50 participants over time. The goal is to identify factors that help doctors …

This study is gathering tumor, blood, and plasma samples from over 1,000 people with certain cancers (ovarian, triple-negative breast, head and neck, cervical, vulva, and sarcoma). The goal is to find new biomarkers that link a tumor's genetic changes and the body's immune respon…

This study aims to understand why some ovarian cancer patients do not respond to platinum-based chemotherapy while others stay cancer-free for years. Researchers will compare genetic, clinical, and tissue samples from 55 patients treated at one center. The goal is to find differe…

This study is creating a large database of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer, how it progresses, and how to improve p…

This study looks at whether a simple blood test can find genetic changes in tumor DNA that signal ovarian cancer is coming back. It involves 130 women with BRCA gene mutations who are taking a maintenance drug called Olaparib (with or without bevacizumab) after initial treatment.…